Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869782 | 1.00 | BRD4 (0.39) | BRD4KMT2AMEN1PDK1PDK2 | |
| SCHEMBL4865526 | 0.95 | KMT2A (0.40) | BRD4KMT2AMEN1PDK1PDK2 | |
| SCHEMBL4869034 | 0.88 | KMT2A (0.42) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4867889 | 0.88 | SMN1; SMN2 (0.43) | BRD4 | |
| SCHEMBL4866466 | 0.88 | SMN1; SMN2 (0.43) | BRD4 | |
| SCHEMBL4867992 | 0.87 | KMT2A (0.43) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4866414 | 0.87 | KMT2A (0.43) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4867620 | 0.86 | KMT2A (0.41) | KMT2AMEN1 | |
| SCHEMBL4864131 | 0.85 | KMT2A (0.36) | KMT2AMEN1PDK1PDK2PDK3 | |
| SCHEMBL4870250 | 0.85 | PDK1 (0.51) | PDK1PDK2PDK3PDK4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | claimed |
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019961-A1 | Estrogen receptor ligands | GPER1, ESR2, ESR1 | BRD4 1413/4885KMT2A 2436/4885MEN1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.